Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 11/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7467592 | 0.87 | TAS1R3 (0.49) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL7463738 | 0.79 | TAS1R3 (0.45) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL14367232 | 0.79 | CTSL (0.39) | CTSKCTSBCTSSCTSLCNR2 | |
| SCHEMBL27545046 | 0.74 | TLR7 (0.45) | CTSKCTSBCTSL | |
| SCHEMBL7609373 | 0.73 | HSPA5 (0.49) | CTSKCTSBCTSSCTSLCNR2 | |
| SCHEMBL7813672 | 0.73 | HSPA5 (0.49) | CTSKCTSBCTSSCTSLUTS2R | |
| SCHEMBL7806106 | 0.73 | HSPA5 (0.49) | CTSKCTSBCTSSCTSLUTS2R | |
| SCHEMBL6620163 | 0.72 | HSPA5 (0.49) | CTSKCTSBCTSSCTSL | |
| SCHEMBL7468998 | 0.72 | CTSK (0.65) | TAS1R3TAS1R1CTSKCTSBCTSS | |
| SCHEMBL7462272 | 0.71 | CTSL (0.50) | TAS1R3TAS1R1CTSKCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | CTSS, CTSD, CTSV | TAS1R3 3745/4885TAS1R1 3504/4885CTSK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.